MAPT and Stroke: As cis P-tau is an early driver and biomarker for incipient and preclinical AD, stroke/VaD, TBI/CTE and cis P-tau mAb is in clinical trials, our results not only discover an early disease driver, but also offer an early biomarker and effective antibody therapy for PE.